The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Molecular targets in heart failure gene therapy: current controversies and translational perspectives
Abstract
Use of gene therapy for heart failure is gaining momentum as a result of the recent successful completion of phase II of the Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID) trial, which showed clinical safety and efficacy of an adeno‐associated viral vector expressing sarco‐endoplasmic reticulum calcium ATPase (SERCA2a). Resorting to gene therapy allows the manipulation of molecular targets not presently amenable to pharmacologic modulation. This short review focuses on the molecular targets of heart failure gene therapy that have demonstrated translational potential. At present, most of these targets are related to calcium handling in the cardiomyocyte. They include SERCA2a, phospholamban, S100A1, ryanodine receptor, and the inhibitor of the protein phosphatase 1. Other targets related to cAMP signaling are reviewed, such as adenylyl cyclase. MicroRNAs are emerging as novel therapeutic targets and convenient vectors for gene therapy, particularly in heart disease. We propose a discussion of recent advances and controversies in key molecular targets of heart failure gene therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In particular, SERCA-directed gene therapy is the most effective strategy to augment Ca2+ transport and muscle contractility, either using an adeno-associated virus to overexpress the ATPase in cardiomyocytes or targeting PLN to reverse SERCA inhibition10.”
From Rheostatic Regulation of the SERCA/Phospholamban Membrane Protein Complex Using Non-Coding RNA and Single-Stranded DNA oligonucleotides (2015) · cites this paper as [10]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Heart Disease and Stroke Statistics—2023 Update: A Report From the American Heart Association
Tsao, C. W., Aday, A. W., Almarzooq, Z. I., Anderson, C. A. M., Arora, P., Avery, C. L., Baker-Smith, C. M., Beaton, A. Z., Boehme, A. K., Buxton, A. E., et al. (2023) · Circulation · doi:10.1161/cir.0000000000001123 · Cited by 8,300
Jaski, B. E., Jessup, M. L., Mancini, D. M., Cappola, T. P., Pauly, D. F., Greenberg, B., Borow, K., Dittrich, H., Zsebo, K. M., & Hajjar, R. J. (2009) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2009.01.013 · Cited by 457
Self-citationPleger, S. T., Shan, C., Ksienzyk, J., Bekeredjian, R., Boekstegers, P., Hinkel, R., Schinkel, S., Leuchs, B., Ludwig, J., Qiu, G., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002097 · Cited by 234
Enhanced Cardiac Function in Transgenic Mice Expressing a Ca 2+ -Stimulated Adenylyl Cyclase
Lipskaia, L., Defer, N., Esposito, G., Hajar, I., Garel, M.-C., Rockman, H. A., & Hanoune, J. (2000) · Circulation Research · doi:10.1161/01.res.86.7.795 · Cited by 67
Self-citation
Research works printed but not linked: 59
- 10.1517/14712590903321462 · DOI · Paper page
- 10.1161/CIR.0b013e3182009701 · DOI · Paper page
- Gheorghiade M., 2011, Combining SERCA2a activation and Na‐K ATPase inhibition: a promising new approach to managing acute heart failure syndromes with low cardiac output, Discov. Med., 12, 141
- 10.1093/eurheartj/ehr026 · DOI · Paper page
- 10.1161/CIRCULATIONAHA.111.022889 · DOI · Paper page
- 10.1161/CIRCULATIONAHA.109.890954 · DOI
- 10.1016/j.jacc.2010.11.023 · DOI
- 10.1161/CIRCULATIONAHA.105.592550 · DOI
- 10.1161/CIRCRESAHA.111.255687 · doi:10.1161/circresaha.111.255687
- 10.1161/CIRCULATIONAHA.108.770883 · DOI
- 10.1016/j.yjmcc.2010.11.011 · DOI
- 10.1161/CIRCEP.110.961615 · DOI · Paper page
- 10.1016/S0092-8674(00)81662-1 · DOI · Paper page
- 10.1161/hc0802.105564 · DOI · Paper page
- 10.1161/CIRCULATIONAHA.108.783852 · DOI · Paper page
- 10.1161/01.RES.0000163981.97262.3b · DOI
- 10.1016/j.jacc.2007.03.047 · DOI · Paper page
- 10.1016/j.bbrc.2011.04.023 · DOI
- 10.1016/S0008-6363(01)00487-4 · DOI · Paper page
- 10.1172/JCI17892 · DOI · Paper page
- 10.1089/hum.2011.035 · DOI
- 10.1074/jbc.M704056200 · DOI · Paper page
- 10.1172/JCI118446 · DOI · Paper page
- 10.1016/j.yjmcc.2011.04.006 · DOI
- 10.1093/cvr/cvr058 · DOI
- 10.1161/01.RES.0000161256.85833.fa · DOI · Paper page
- 10.1038/nature10407 · DOI · Paper page
- 10.1016/j.jacc.2011.04.032 · DOI
- 10.1016/j.jacc.2011.03.054 · DOI
- 10.1038/ncpcardio0309 · DOI
- 10.2217/14796678.3.4.413 · DOI
- 10.1161/CIRCRESAHA.108.173195 · DOI
- 10.1161/01.CIR.99.12.1618 · DOI · Paper page
- 10.1093/eurheartj/15.suppl_D.7 · doi:10.1093/eurheartj/15.suppl_d.7
- 10.1161/01.RES.0000102042.83024.CA · DOI · Paper page
- Ostrom R.S., 2000, Stoichiometry and compartmentation in G protein‐coupled receptor signaling: implications for therapeutic interventions involving G(s), J. Pharmacol. Exp. Ther., 294, 407, 10.1016/S0022-3565(24)39086-X · DOI · Paper page
- 10.1152/ajprenal.2000.279.3.F400 · DOI · Paper page
- 10.1146/annurev.pharmtox.41.1.145 · DOI · Paper page
- 10.1016/S0014-5793(98)00747-9 · doi:10.1016/s0014-5793(98)00747-9
- 10.1038/sj.bjp.0705976 · DOI
- 10.1152/ajpheart.00050.2009 · DOI
- 10.1016/S0008-6363(98)00283-1 · DOI
- 10.1021/bi991619k · DOI
- 10.1253/circj.CJ-08-0957 · DOI
- 10.1073/pnas.1733772100 · DOI · Paper page
- 10.1016/j.jacc.2010.11.052 · DOI
- 10.1074/jbc.M805825200 · DOI
- 10.1016/j.cellsig.2009.11.010 · DOI
- Lipskaia L., 2011, Compartmentalization of cAMP increase at the level of sarcoplasmic reticulum results in dilated and hypertrophic cardiomyopathy in aged transgenic mice, Eur. Heart J., 32, 999
- 10.1096/fj.02-0292fje · DOI
- 10.1096/fj.02-0784com · DOI
- 10.1002/eji.201041136 · DOI · Paper page
- 10.1136/hrt.2007.116483 · DOI
- 10.1016/j.pharmthera.2010.09.011 · DOI · Paper page
- 10.1016/j.yjmcc.2006.08.008 · DOI
- 10.2353/ajpath.2010.090451 · DOI
- 10.1097/FJC.0b013e3181f713fe · DOI
- 10.1161/CIRCRESAHA.110.227496 · DOI · Paper page
- Karakikes I., 2010, Abstract 20916: therapeutic cardiac‐targeted delivery of Mir‐1 reverses hypertrophy and preserves cardiac function in a pressure overload animal model, Circulation, 122, A20916
Cited by
MicroRNAs and cardiovascular diseases
Ono, K., Kuwabara, Y., & Han, J. (2011) · The FEBS Journal · doi:10.1111/j.1742-4658.2011.08090.x · Cited by 169
Soller, K. J., Yang, J., Veglia, G., & Bowser, M. T. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.738807 · Cited by 20
Soller, K. J., Verardi, R., Jing, M., Abrol, N., Yang, J., Walsh, N., Vostrikov, V. V., Robia, S. L., Bowser, M. T., & Veglia, G. (2015) · Scientific Reports · doi:10.1038/srep13000 · Cited by 12
Metadata
- Authors
- Kairouz, V., Lipskaia, L., Hajjar, R. J., & Chemaly, E. R.
- Venue
- Annals of the New York Academy of Sciences
- Publisher
- Wiley
- Published
- 2012-04
- Volume
- 1254
- Issue
- 1
- Pages
- 42-50
- ISSN
- 0077-8923
- 1749-6632
- Cited by
- 42
- References
- 4
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.